By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shire Pharmaceuticals Group plc 

Hampshire International Business Park
Basingstoke  Hampshire  RG24 8EP  United Kingdom
Phone: 44-1256-894-000 Fax: 44-1256-894-708


Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.

By 1992, Shire had embarked on the first of what would be a series of strategic acquisitions -- these were bold ventures that fortified our product lines and underscored the wisdom of a business model focused exclusively on products sold to specialist physicians. After the turn of the millennium, with the acquisition of TKT, we began our focus on rare diseases, something that remains a strategic focus for the company today. The Shire pipeline continues to be sustained by creative acquisitions and innovative licensing deals. Smart commercialization strategies have ensured that the right patients and the right physicians have the information they need to make appropriate choices about treatment options.

In June 2016, Shire completed a combination with Baxalta, creating the world’s leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.




FOUNDER: Harry Stratford

CEO: Flemming Ornskov

CFO: Jeffrey Poulton


Please click here for Shire job opportunities..


Please click here for clinical trial information..


Please click here for product information..


Key Statistics

Ownership: Public

Web Site: Shire
Symbol: SHPG


Company News
David Lee Appointed Head Of Global Oncology For Shire (SHPG) 10/27/2016 12:27:19 PM
Results From Shire (SHPG)'s Phase 2 Study Of Maribavir Showed Activity Against CMV Infection In Patients Undergoing Transplant 10/27/2016 10:37:46 AM
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT) 10/24/2016 5:52:16 AM
Shire (SHPG) Granted EU Marketing Authorization Of Onivyde, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV),For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas In Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy 10/18/2016 10:51:19 AM
Shire (SHPG) Announces Update To Vyvanse (Lisdexamfetamine Dimesylate) U.S. Labeling To Include New Longer-Term Maintenance Of Efficacy Data In Adults With Moderate To Severe Binge Eating Disorder 10/17/2016 7:28:52 AM
Shire (SHPG) Release: Patent Trial And Appeal Board Upholds The Validity Of LIALDA Patent 10/6/2016 7:18:19 AM
Kamada Ltd. (KMDA) Announces Extension Of GLASSIA® Supply And Distribution Agreement With Shire (SHPG) With Minimum $237 Million Of Revenue For The Years 2017 To 2020 10/6/2016 7:12:18 AM
Shire (SHPG) Terminates a Couple of Biosimilar Deals Made by Baxalta (BXLT) 9/27/2016 6:35:57 AM
The Bobble-Head Doll In The Office Of Shire (SHPG) CEO Flemming Ornskov 9/26/2016 7:12:44 AM
Shire (SHPG) To Showcase Continued Innovation And Leadership In Immune Deficiencies During European Society For Immunodeficiencies Biennial Meeting 9/23/2016 10:57:58 AM